FMOD expression in whole blood aids in distinguishing between chronic lymphocytic leukemia and other leukemic lymphoproliferative disorders. A pilot study
| Autor: | Sílvia Beà, Diana Marcela Ruíz Domínguez, Sara Vergara, Esther Plensa, Silvia-Zdenka Mostacedo, Andrea Espasa, Marc Sorigue, Christelle Ferra, Laia Pinyol, Rocio Ruiz, Joan Buch, Jessica Aranda, Lurdes Zamora, Gustavo Tapia, Marta Cabezón, Silvia Marcé, Neus Ruiz-Xivillé, Isabel Granada, Laia Lopez-Viaplana, José-Tomás Navarro, Jordi Juncà, Minerva Raya |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine Oncology medicine.medical_specialty Histology Cytodiagnosis Chronic lymphocytic leukemia Lymphocyte Lymphoproliferative disorders Pathology and Forensic Medicine Diagnosis Differential 03 medical and health sciences 0302 clinical medicine immune system diseases Interquartile range hemic and lymphatic diseases Internal medicine medicine Humans Lymphocyte Count Aged Aged 80 and over business.industry CD23 Cell Biology Flow Cytometry medicine.disease Leukemia Lymphocytic Chronic B-Cell Lymphoproliferative Disorders Gene Expression Regulation Neoplastic Haematopoiesis 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Female CD5 business Trisomy Fibromodulin |
| Zdroj: | Cytometry Part B: Clinical Cytometry. 98:421-428 |
| ISSN: | 1552-4957 1552-4949 |
| Popis: | BACKGROUND Within the hematopoietic compartment, fibromodulin (FMOD) is almost exclusively expressed in chronic lymphocytic leukemia (CLL) lymphocytes. We set out to determine whether FMOD could be of help in diagnosing borderline lymphoproliferative disorders (LPD). METHODS We established 3 flow cytometry-defined groups (CLL [n = 65], borderline LPD [n = 28], broadly defined as those with CLLflow score between 35 and -20 or discordant CD43 and CLLflow, and non-CLL LPD [n = 40]). FMOD expression levels were determined by standard RT-PCR in whole-blood samples. Patients were included regardless of lymphocyte count but with tumor burden ≥40%. RESULTS FMOD expression levels distinguished between CLL (median 98.5, interquartile range [IQR] 37.8-195.1) and non-CLL LPD (median 0.012, IQR 0.003-0.033) with a sensitivity and specificity of 1. Most borderline LPDs were CD5/CD23/CD200-positive with no loss of B-cell antigens and negative or partial expression of CD43. 16/22 patients with available cytogenetic analysis showed trisomy 12. In 25/28 (89%) of these patients, FMOD expression levels fell between CLL and non-CLL (median 3.58, IQR 1.06-6.21). DISCUSSION This study could suggest that borderline LPDs may constitute a distinct group laying in the biological spectrum of chronic leukemic LPDs. Future studies will have to confirm these results with other biological data. Quantification of FMOD can potentially be of help in the diagnosis of phenotypically complex LPDs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text